Riskpilot← Back to searchSign inGet full accessInnopart Oy
OYActiveY-tunnus 3213071-5Kirjapainontie 8Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2021— employeeswww.innopart.fi
Revenue 2025
EUR 368K
+41% vs 2024
EBITDA margin
21.6%
+350% vs 2024
Equity ratio
34.0%
Financial strength
Net profit 2025
EUR 42K
+359% vs 2024
| Revenue | EUR 368K | +41% |
| EBITDA | EUR 79K | +350% |
| Net profit | EUR 42K | +359% |
| Total assets | EUR 206K | +17% |
| Equity | EUR 70K | +152% |
| Employees | — | — |
Legal name
Innopart Oy
Y-tunnus number
3213071-5
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
24. toukokuuta 2021
Share capital
EUR 0
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-10-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiö harjoittaa terveydenhuoltoon soveltuvien kalusteiden valmistusta, tuotekehitystä, myyntiä, vientiä ja tuontia. Lisäksi yhtiön toimialaan kuuluu konsultointi, urheiluvälinetelineiden myynti sekä kaikki laillinen liiketoiminta. Yhtiö voi omistaa ja hallita kotimaisia ja ulkomaisia kiinteistöjä, osakehuoneistoja sekä arvopapereita, käydä niillä kauppaa ja harjoittaa huoneistojen vuokraustoimintaa.
Address
Kirjapainontie 8
Website
www.innopart.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 340 | 265 | 261 | 368 |
| Staff expenses | −83 | −75 | −94 | −93 |
| EBITDA | 62 | 57 | 18 | 79 |
| Depreciation & amort. | −37 | −20 | −23 | −23 |
| EBIT | 25 | 38 | −6 | 56 |
| Net financials | −15 | −5 | −11 | −7 |
| Profit before tax | 10 | 33 | −16 | 49 |
| Tax | 2 | 7 | −0 | 7 |
| Net profit | 8 | 26 | −16 | 42 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 246 | 232 | 176 | 206 |
| Equity | 8 | 34 | 28 | 70 |
| Long-term debt | 162 | 131 | 99 | 68 |
| Short-term debt | 76 | 67 | 49 | 68 |
| Total debt | 238 | 197 | 149 | 136 |
EBITDA margin
21.6%
This company
15.8%
Market median
+37% vs market
20222025
Equity ratio
34.0%
This company
38.2%
Market median
+11% vs market
20222025
Return on equity
60.3%
This company
18.4%
Market median
+228% vs market
20222025
Net profit margin
11.5%
This company
8.1%
Market median
+42% vs market
20222025
Asset turnover
1.79×
This company
1.12×
Market median
+60% vs market
20222025
Debt / equity
1.94×
This company
0.62×
Market median
-213% vs market
20222025
- Annual report 2025Filed via PRH / YTJ · Period 2024-11-01 – 2025-10-31
- Annual report 2024Filed via PRH / YTJ · Period 2023-11-01 – 2024-10-31
- Annual report 2023Filed via PRH / YTJ · Period 2022-11-01 – 2023-10-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-05-24 – 2022-10-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
TT Audit | Audit | 2023 |
MK Deputy auditor | Deputy auditor | 2023 |
KK Chief Executive Officer | Chief Executive Officer | 2021 |
HJ Deputy Member | Deputy Member | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairperson | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Innopart Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tuomo Tapio Vire | Audit | 0 companies |
| Marjo Kaija Helena Lähteenmaa | Deputy auditor | 0 companies |
| Kukka-Maaria Kenkkilä | Chief Executive Officer | 0 companies |
| Herman Johannes Kenkkilä | Deputy Member | 0 companies |
| Kimmo Sakari Niska | Chairperson | 0 companies |